Treatment of ARB202 Advanced Gastrointestinal Cancer Patients
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
This study aims to find out:
1. The tolerability of ARB202 in adults with advanced solid gastrointestinal tumors who
failed the standard treatment. People can participate if their tumor has the CDH17
marker.
2. To find out how study drug is broken down in the body
3. To know the effects of the study drug on the tumor.